← Eichor
Study identifier: NCT02920554 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Effect in Wedge Resection and IVb/V Resection of the Liver for Gallbladder Cancer

Condition: Gallbladder Cancer  ·  Sponsor: Saint Vincent's Hospital, Korea

PhaseNA
Planned participants88
Who can joinAll sexes, 19 Years to 80 Years
Healthy volunteersNo

About this study

The extent of hepatic resection for gallbladder cancer can be done from a wedge resection to 4b/5 bisegmentectomy. This study aims to compare the recurrence rates and survival rates between wedge resection group and bisegmentectomy group. Patients with T2 or T3 gallbladder cancer on preoperative CT exam or patients who were pathologically diagnosed as T2 or T3 gallbladder cancer after initial simple cholecystectomy were enrolled. All patients are randomly assigned to wedge resection or bisegmentectomy group. Number of patients in each group is 44. Primary endpoint is recurrence-free-survival rates and overall survival rates.

This description comes directly from the study's public registry record.

Talk to the study team

Dong Do You, MD, PhD  ·  82-31-249-8303  ·  tzanggu@catholic.ac.kr

Kwang Yeol Paik, MD, PhD  ·  kpaik@catholic.ac.kr

Always discuss trial participation with your own doctor first.

Locations (1)

the Catholic University of Korea St. Vincent's HospitalSuwon, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02920554